New FDA Regulatory Framework Proposed for Hospital AI
The proposal mandates FDA certification for internal AI to replace the current fragmented oversight of medical models.
Updated on Oct. 15, 2026 in Artificial Intelligence
Live Poll
Should Congress enact stricter federal regulatory oversight for AI models used in academic medical centers?
Scott Gottlieb has proposed a new federal regulatory framework to bring internal artificial intelligence models at academic medical centers under FDA oversight. Currently, these institutions develop and deploy AI tools internally to bypass standard federal device regulations.
Why it matters
The current oversight gap creates a two-tier market where academic AI lacks the consistent vetting required for commercial developers, leading to inconsistent model performance and bias testing. Standardizing these regulations aims to align internal hospital systems with the safety benchmarks expected of commercial device developers.
Surveys show that only 61% of hospitals test predictive models with local data, while 44% assess them for bias. These figures highlight the lack of uniform standards compared to the rigorous requirements mandated for commercial medical device developers.
The players
Scott Gottlieb
A fellow at the American Enterprise Institute who is advocating for new federal oversight of medical AI.
FDA
The federal agency that would be empowered to certify health systems and monitor AI algorithm performance.
CMS
The federal agency that currently administers the Clinical Laboratory Improvement Amendments for laboratory testing.
The details
The proposed framework would empower the FDA to certify health systems for the development and deployment of specific AI categories. It requires these institutions to regularly submit algorithm performance data to the agency, a shift from current practices that operate under the Clinical Laboratory Improvement Amendments—federal standards that regulate laboratory testing—administered by the Centers for Medicare & Medicaid Services.
Timeline
2025: Brian Richard Jackson published a study on AI regulation.
October 15, 2026: Scott Gottlieb published his opinion piece in JAMA Health Forum.
The Tech Race
This proposal seeks to end the current bifurcated landscape where academic labs operate under the Clinical Laboratory Improvement Amendments rather than stricter FDA device oversight. It represents a policy push to close the gap between internal institutional R&D and established commercial medical device standards.
If enacted, this framework would change how academic medical centers deploy AI diagnostics and predictive tools by necessitating federal certification. Implementation would require an act of Congress, meaning the shift to mandatory performance reporting is not yet imminent.
The takeaway
The proposal highlights a critical need to standardize AI validation across all medical settings to ensure patient safety. Watch for potential legislative activity in Congress to authorize the FDA to oversee these currently internal academic AI systems.
Further reading
For broader trends in algorithmic oversight, explore our coverage of Artificial Intelligence.
Source note: This article includes information reported by Raps.
Live Poll
Should Congress enact stricter federal regulatory oversight for AI models used in academic medical centers?
